These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22761921)

  • 1. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
    Koo DH; Park CY; Lee ES; Ro J; Oh SW
    PLoS One; 2012; 7(6):e39880. PubMed ID: 22761921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.
    Serrero G; Hawkins DM; Yue B; Ioffe O; Bejarano P; Phillips JT; Head JF; Elliott RL; Tkaczuk KR; Godwin AK; Weaver J; Kim WE
    Breast Cancer Res; 2012 Feb; 14(1):R26. PubMed ID: 22316048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study.
    Koo DH; Lee KS; Sim SH; Chae H; Lee EG; Han JH; Jung SY; Lee S; Kang HS; Lee ES; Park CY; Oh SW
    Breast Cancer (Dove Med Press); 2023; 15():251-261. PubMed ID: 37081941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
    Berger K; Rhost S; Rafnsdóttir S; Hughes É; Magnusson Y; Ekholm M; Stål O; Rydén L; Landberg G
    BMC Cancer; 2021 Feb; 21(1):185. PubMed ID: 33618683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection.
    Koo DH; Do IG; Oh S; Lee YG; Kim K; Sohn JH; Park SK; Yang HJ; Jung YS; Park DI; Jeong KU; Kim HO; Kim H; Serrero G; Chun HK;
    Pathol Oncol Res; 2020 Jan; 26(1):397-404. PubMed ID: 30378010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study.
    Oh SW; Park CY; Lee ES; Yoon YS; Lee ES; Park SS; Kim Y; Sung NJ; Yun YH; Lee KS; Kang HS; Kwon Y; Ro J
    Breast Cancer Res; 2011 Mar; 13(2):R34. PubMed ID: 21450081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
    Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
    Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
    JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.